Insider · CIK 0001840738
John Brendan Doyle
Files at CGTX (COGNITION THERAPEUTICS INC). First filing Apr 20, 2026, latest Apr 20, 2026.
John Brendan Doyle files SEC Form 4 as CFO at CGTX (COGNITION THERAPEUTICS INC). Since Apr 20, 2026, John Brendan Doyle has reported 1 open-market buy worth $11k and 0 open-market sells worth $0, the latest filed on Apr 20, 2026.
A track record needs three past buys with six months of prices behind them; John Brendan Doyle has 0, so none is measured yet.
The newest scored trade: bought $11k of CGTX on Apr 16, 2026, filed Apr 20, 2026, scored 45 (moderate). In the last 12 months: 1 buy worth $11k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGTX: COGNITION THERAPEUTICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | COGNITION THERAPEUTICS INC | $11k 10,000 shares | +2% | +364% from low-65% from high |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -8,567 | $1.28 | $11k | 618,942 | May 4, 2026 |
| Apr 16, 2026 | CGTX COGNITION THERAPEUTICS INC | POpen-market purchase Common Stock | +10,000 | $1.13 | $11k | 627,509 | Apr 20, 2026 |
| Feb 15, 2026 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -1,560 | $1.12 | $1,747 | 617,509 | Feb 18, 2026 |
| Feb 3, 2026 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 645,990 | Feb 5, 2026 |
| Feb 4, 2026 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -26,921 | $1.03 | $28k | 619,069 | Feb 5, 2026 |
| Dec 18, 2025 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 455,350 | Dec 22, 2025 |
| Dec 18, 2025 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -9,360 | $1.50 | $14k | 445,990 | Dec 22, 2025 |
| Jul 29, 2025 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 434,710 | Jul 31, 2025 |
| Jul 29, 2025 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -9,360 | $0.67 | $6,273 | 425,350 | Jul 31, 2025 |
| May 1, 2025 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -9,692 | $0.45 | $4,334 | 404,710 | May 2, 2025 |
| Feb 15, 2025 | CGTX COGNITION THERAPEUTICS INC | FTax withholding Common Stock | -1,723 | $0.59 | $1,017 | 414,402 | Feb 18, 2025 |
| Feb 4, 2025 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +295,000 | $0.00 | $0 | 416,125 | Feb 4, 2025 |
Questions about John Brendan Doyle
Answered from the filings on this page, as of the latest one.
Is John Brendan Doyle buying or selling?
In the last 12 months John Brendan Doyle reported 1 open-market buy worth $11k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $11k of CGTX on Apr 16, 2026. Grants, option exercises and tax withholding are not counted.
How did John Brendan Doyle's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Brendan Doyle has 0.
Where does John Brendan Doyle file Form 4?
John Brendan Doyle has filed Form 4 at CGTX (COGNITION THERAPEUTICS INC) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.